TD Waterhouse Canada’s XORTX Therapeutics XRTX Stock Holding History

TD Waterhouse Canada’s Portfolio XRTX Stock Details XRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19	Hold	9	–	–	﹤0.01%	2373
2026 Q1	$19	Buy	+9	New	+$21	﹤0.01%	2275

Other funds holding XRTX

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return

Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

TD Waterhouse Canada's XRTX Position: Q2 2026 in Review

TD Waterhouse Canada held its XORTX Therapeutics (XRTX) position steady in Q2 2026 at 9 shares worth $19. The position accounts for ﹤0.01% of the portfolio, ranked #2373.

TD Waterhouse Canada first reported a position in XRTX in Q1 2026 and has held it in 2 quarters since. 6 funds tracked by Wall St. Rank hold XRTX as of Q2 2026.

TD Waterhouse Canada held 9 shares of XORTX Therapeutics worth $19 as of Q2 2026.
TD Waterhouse Canada left its XORTX Therapeutics share count unchanged in Q2 2026.
XORTX Therapeutics made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q2 2026, its #2373 holding.
TD Waterhouse Canada first reported a position in XORTX Therapeutics in Q1 2026 and has held it in 2 quarters since.
6 funds tracked by Wall St. Rank held XORTX Therapeutics as of Q2 2026.

Based on TD Waterhouse Canada's 13F filing for Q2 2026, filed 27 Jul 2026.